Form 8-K Valeant Pharmaceuticals For: Aug 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery
August 10, 2016 9:54 AM EDTBTIG affirms Valeant Phama (NYSE: VRX) at Neutral following Q2 results from the company.
Analyst Timothy Chiang commented, While quarterly results were mixed, the Co. maintained its full year financial targets (which include revenues of $9.9 - $10.1B and EPS of $6.60 - $7.00). While... More
RBC Affirms Valeant (VRX) at 'Sector Perform'; Q2 Slightly Below Views, Walgreens Derm co-Pay Shows Improvement
August 9, 2016 9:32 AM EDTRBC affirms Valeant (NYSE: VRX) Sector Perform with a price target of $31 following Q2 results on Tuesday.
Analyst Douglas Miehm offered the following quick commentary ahead of the company's conference call:
Total revenues in Q2/16 were $2.42B vs. our forecast of $2.47B, and consensus of $2.47B (FactSet,15 analysts, $2.30-2.66B range). Relative to our forecasts, the Derm, GI, and Neuro/Other segments came in below our expectations, and the Emerging... More
